tiprankstipranks
Trending News
More News >
Innovent Biologics (HK:1801)
:1801
Hong Kong Market

Innovent Biologics (1801) Financial Statements

Compare
10 Followers

Innovent Biologics Financial Overview

Innovent Biologics's market cap is currently $84.13B. The company's EPS TTM is HK$-0.064; its P/E ratio is ―; Innovent Biologics is scheduled to report earnings on March 26, 2025, and the estimated EPS forecast is HK$0.20. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue¥ 9.42B¥ 6.21B¥ 4.56B¥ 4.27B¥ 3.84B
Gross Profit¥ 7.91B¥ 4.40B¥ 3.63B¥ 3.70B¥ 3.46B
Operating Income¥ -755.87M¥ -1.68B¥ -2.07B¥ -3.11B¥ -820.14M
EBITDA¥ -480.28M¥ -660.68M¥ -1.75B¥ -2.37B¥ -704.74M
Net Income¥ -94.63M¥ -1.03B¥ -2.18B¥ -3.14B¥ -998.42M
Balance Sheet
Cash & Short-Term Investments¥ 7.88B¥ 10.97B¥ 8.26B¥ 7.94B¥ 8.05B
Total Assets¥ 21.60B¥ 20.63B¥ 17.59B¥ 16.24B¥ 11.83B
Total Debt¥ 2.83B¥ 3.62B¥ 3.23B¥ 2.50B¥ 1.21B
Net Debt¥ -4.68B¥ -6.43B¥ 2.21B¥ 1.14B¥ -69.61M
Total Liabilities¥ 8.48B¥ 8.10B¥ 6.86B¥ 5.91B¥ 3.06B
Stockholders' Equity¥ 13.12B¥ 12.53B¥ 10.73B¥ 10.33B¥ 8.78B
Cash Flow
Free Cash Flow¥ 0.00¥ -1.24B¥ -3.30B¥ -3.87B¥ -1.08B
Operating Cash Flow¥ 0.00¥ 147.81M¥ -1.92B¥ -2.02B¥ -307.69M
Investing Cash Flow¥ 0.00¥ -998.66M¥ -1.44B¥ -2.70B¥ -5.18B
Financing Cash Flow¥ 0.00¥ 2.59B¥ 2.89B¥ 5.00B¥ 4.91B
Currency in CNY

Innovent Biologics Earnings and Revenue History

Innovent Biologics Debt to Assets

Innovent Biologics Cash Flow

Innovent Biologics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis